212 related articles for article (PubMed ID: 11750224)
1. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
Weeratna RD; Brazolot Millan CL; McCluskie MJ; Davis HL
FEMS Immunol Med Microbiol; 2001 Dec; 32(1):65-71. PubMed ID: 11750224
[TBL] [Abstract][Full Text] [Related]
2. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
[TBL] [Abstract][Full Text] [Related]
3. Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12.
Schirmbeck R; Reimann J
Intervirology; 2001; 44(2-3):115-23. PubMed ID: 11509872
[TBL] [Abstract][Full Text] [Related]
4. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
McCluskie MJ; Davis HL
J Immunol; 1998 Nov; 161(9):4463-6. PubMed ID: 9794366
[TBL] [Abstract][Full Text] [Related]
5. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice.
Brazolot Millan CL; Weeratna R; Krieg AM; Siegrist CA; Davis HL
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15553-8. PubMed ID: 9861007
[TBL] [Abstract][Full Text] [Related]
6. Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies.
Weeratna RD; Brazolot Millan CL; McCluskie MJ; Siegrist CA; Davis HL
FEMS Immunol Med Microbiol; 2001 Apr; 30(3):241-7. PubMed ID: 11335145
[TBL] [Abstract][Full Text] [Related]
7. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
Wild J; Grusby MJ; Schirmbeck R; Reimann J
J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
[TBL] [Abstract][Full Text] [Related]
8. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.
McCluskie MJ; Weeratna RD; Davis HL
Vaccine; 2001 Mar; 19(17-19):2657-60. PubMed ID: 11257405
[TBL] [Abstract][Full Text] [Related]
9. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Clin Chem Lab Med; 1999 Mar; 37(3):199-204. PubMed ID: 10353461
[TBL] [Abstract][Full Text] [Related]
10. Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes.
McCluskie MJ; Wen YM; Di Q; Davis HL
Viral Immunol; 1998; 11(4):245-52. PubMed ID: 10189191
[TBL] [Abstract][Full Text] [Related]
11. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
McCluskie MJ; Weeratna RD; Davis HL
Mol Med; 2000 Oct; 6(10):867-77. PubMed ID: 11126201
[TBL] [Abstract][Full Text] [Related]
12. CpG DNA induces stronger immune responses with less toxicity than other adjuvants.
Weeratna RD; McCluskie MJ; Xu Y; Davis HL
Vaccine; 2000 Mar; 18(17):1755-62. PubMed ID: 10699323
[TBL] [Abstract][Full Text] [Related]
13. DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response.
Whalen RG; Leclerc C; Dériaud E; Schirmbeck R; Reimann J; Davis HL
Ann N Y Acad Sci; 1995 Nov; 772():64-76. PubMed ID: 8546414
[TBL] [Abstract][Full Text] [Related]
14. CpG DNA as mucosal adjuvant.
McCluskie MJ; Davis HL
Vaccine; 1999 Sep; 18(3-4):231-7. PubMed ID: 10506647
[TBL] [Abstract][Full Text] [Related]
15. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans.
Davis HL; Suparto II; Weeratna RR; Jumintarto ; Iskandriati DD; Chamzah SS; Ma'ruf AA; Nente CC; Pawitri DD; Krieg AM; Heriyanto ; Smits W; Sajuthi DD
Vaccine; 2000 Mar; 18(18):1920-4. PubMed ID: 10699341
[TBL] [Abstract][Full Text] [Related]
16. The influence of CpG motifs on a protein or DNA-based Th2-type immune response against major pollen allergens Bet v 1a, Phl p 2 and Escherichia coli-derived beta-galactosidase.
Hochreiter R; Hartl A; Freund J; Valenta R; Ferreira F; Thalhamer J
Int Arch Allergy Immunol; 2001; 124(1-3):406-10. PubMed ID: 11307030
[TBL] [Abstract][Full Text] [Related]
17. Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine.
Brunel F; Darbouret A; Ronco J
Vaccine; 1999 Apr; 17(17):2192-203. PubMed ID: 10367954
[TBL] [Abstract][Full Text] [Related]
18. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
Chu RS; Targoni OS; Krieg AM; Lehmann PV; Harding CV
J Exp Med; 1997 Nov; 186(10):1623-31. PubMed ID: 9362523
[TBL] [Abstract][Full Text] [Related]
19. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes.
Chow YH; Chiang BL; Lee YL; Chi WK; Lin WC; Chen YT; Tao MH
J Immunol; 1998 Feb; 160(3):1320-9. PubMed ID: 9570550
[TBL] [Abstract][Full Text] [Related]
20. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.
McCluskie MJ; Brazolot Millan CL; Gramzinski RA; Robinson HL; Santoro JC; Fuller JT; Widera G; Haynes JR; Purcell RH; Davis HL
Mol Med; 1999 May; 5(5):287-300. PubMed ID: 10390545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
